온라인 세미나 초록

The new network of sphinogolipid metabolism in the development of non-alcholic steatohepatitis

Nonalcoholic fatty liver disease (NAFLD) has become a major health issue worldwide. Approximately 10–20% of patients with NAFLD develop non-alcoholic steatohepatitis (NASH), an advanced stage of NAFLD that may subsequently progress to liver cirrhosis and hepatocellular carcinoma.

The mechanism by which simple steatosis progresses to NASH and liver fibrosis is not completely understood, and an effective treatment for halting the progression of NASH is yet to be discovered. Lipotoxic hepatocyte death may be the primary lesion that causes liver inflammation and fibrosis. Damage-associated molecular patterns released from dying hepatocytes may activate hepatic macrophages, and secretion of proinflammatory and fibrogenic cytokines from macrophages promotes hepatic stellate cells activation. But the mechanisms of lipotoxicity are not fully defined. Sphingolipids mediate liver injury, but their link in NASH has not been explored. In this presentation, I will introduce the role of sphingolipid metabolism in hepatocyte injury and macrophage activation with inflammasome activation.